cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)

P1, N=20, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2026 --> Dec 2025

5 days ago

Enrollment open • Trial initiation date

doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)

S2206: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (clinicaltrials.gov)

P3, N=3680, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2027 --> May 2032 | Trial primary completion date: May 2027 --> May 2032

7 days ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative

MammaPrint®

Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin

NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)

P2, N=42, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Mar 2026

8 days ago

Trial completion • Trial completion date

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)

MYCN amplification

cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane

12d

A gene signature derived from leukemia associated macrophages provides a compelling risk stratification for human AML patients. (PubMed, Biomark Res)

This scoring system was then applied to the transcriptomic data from a cohort of 838 newly diagnosed patients treated on Alliance/CALGB protocols, who were similarly treated with intensive cytarabine/daunorubicin-based chemotherapy on the CALGB/Alliance for the Clinical Trials in Oncology protocol. We also noted a strong association of FLT3-ITD, RUNX1 and TP53 mutations with high LAM scores. Applying the LAM score to the current European Leukemia Network risk group criteria, independent prognostic implications and a refined prognostic significance of each subgroup were provided, indicating the value of including immune microenvironment data into AML risk stratification.

12 days ago

Journal • Gene Signature

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • FGFR1 (Fibroblast growth factor receptor 1) • RUNX1 (RUNX Family Transcription Factor 1)

TP53 mutation • FLT3-ITD mutation • RUNX1 mutation

cytarabine • daunorubicin

12d

Identification and validation of a prognostic risk-scoring model in drug-resistant ALL and evaluation of immune micro-environment. (PubMed, Ann Hematol)

In cell-line-derived xenografts and humanized mice, triple therapy combining CD40 agonist, daunorubicin and PD-L1 blockade achieved superior leukemia control, prolonged survival and fostered immune memory formation. These findings provide a clinically applicable prognostic tool and pre-clinical rationale for integrating CD40-centered immunotherapy into frontline protocols to overcome chemotherapy resistance in childhood ALL.

12 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD40 (CD40 Molecule) • STAT5A (Signal Transducer And Activator Of Transcription 5A)

daunorubicin

13d

A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients (clinicaltrials.gov)

13 days ago

Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date

KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2)

cytarabine • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Revuforj (revumenib)

13d

AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov)

P3, N=5949, Completed, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Mar 2026 | Active, not recruiting --> Completed

13 days ago

Trial completion • Trial completion date

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6)

MLL rearrangement

dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

13d

NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P1, N=24, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027

13 days ago

Enrollment closed • Trial completion date • Trial primary completion date

Venclexta (venetoclax) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • Starasid (cytarabine ocfosfate)

14d

AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)

P3, N=1645, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2027 --> Mar 2026

14 days ago

Trial completion • Trial completion date

FLT3-ITD mutation

sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)

19d

MM1YA-A04: Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) (clinicaltrials.gov)

P2, N=162, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting

19 days ago

Enrollment open

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)

Venclexta (venetoclax) • cytarabine • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)

23d

Natural and in vitro-generated regulatory T-cell subsets differentially modulate phenotype and drug response in K562 leukemic cells. (PubMed, Cancer Treat Res Commun)

All Treg subsets attenuated daunorubicin cytotoxicity, whereas reduced sensitivity to gemcitabine was observed only in iTreg- and Tr1-containing cultures. These findings suggest that Treg cell subsets may directly promote stemness-associated and drug-tolerance-related features in K562 cells in vitro, supporting a tumor-promoting role within the leukemia microenvironment and warranting further validation in primary leukemia samples and in vivo models.

23 days ago

Preclinical • Journal

PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • FLT1 (Fms-related tyrosine kinase 1) • IL2RA (Interleukin 2 receptor, alpha) • CD34 (CD34 molecule) • IL10 (Interleukin 10) • CD24 (CD24 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3)

gemcitabine • daunorubicin